PROGYNY INC (PGNY) Stock Fundamental Analysis
NASDAQ:PGNY - Nasdaq - US74340E1038 - Common Stock
Taking everything into account, PGNY scores 7 out of 10 in our fundamental rating. PGNY was compared to 108 industry peers in the Health Care Providers & Services industry. PGNY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PGNY is valued quite expensive, but it does show an excellent growth. These ratings would make PGNY suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
PGNY had positive earnings in the past year.
PGNY had a positive operating cash flow in the past year.
Of the past 5 years PGNY 4 years were profitable.
Of the past 5 years PGNY 4 years had a positive operating cash flow.
1.2 Ratios
PGNY's Return On Assets of 8.68% is amongst the best of the industry. PGNY outperforms 93.46% of its industry peers.
Looking at the Return On Equity, with a value of 13.17%, PGNY belongs to the top of the industry, outperforming 82.24% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 12.72%, PGNY belongs to the top of the industry, outperforming 91.59% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for PGNY is in line with the industry average of 8.27%.
The 3 year average ROIC (8.61%) for PGNY is below the current ROIC(12.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 13.17% | ||
| ROIC | 12.73% |
ROA(3y)10.72%
ROA(5y)8.95%
ROE(3y)15.14%
ROE(5y)13.15%
ROIC(3y)8.61%
ROIC(5y)7.94%
1.3 Margins
PGNY's Profit Margin of 5.03% is amongst the best of the industry. PGNY outperforms 83.18% of its industry peers.
In the last couple of years the Profit Margin of PGNY has declined.
PGNY has a better Operating Margin (5.75%) than 67.29% of its industry peers.
PGNY's Operating Margin has improved in the last couple of years.
PGNY has a Gross Margin (21.68%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of PGNY has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.75% | ||
| PM (TTM) | 5.03% | ||
| GM | 21.68% |
OM growth 3Y28.9%
OM growth 5YN/A
PM growth 3Y-24.95%
PM growth 5YN/A
GM growth 3Y2.58%
GM growth 5Y3.57%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PGNY is still creating some value.
The number of shares outstanding for PGNY has been increased compared to 1 year ago.
PGNY has more shares outstanding than it did 5 years ago.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
PGNY has an Altman-Z score of 7.72. This indicates that PGNY is financially healthy and has little risk of bankruptcy at the moment.
PGNY's Altman-Z score of 7.72 is amongst the best of the industry. PGNY outperforms 92.52% of its industry peers.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.72 |
ROIC/WACC1.38
WACC9.25%
2.3 Liquidity
PGNY has a Current Ratio of 2.62. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY's Current ratio of 2.62 is amongst the best of the industry. PGNY outperforms 83.18% of its industry peers.
PGNY has a Quick Ratio of 2.62. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY has a Quick ratio of 2.62. This is amongst the best in the industry. PGNY outperforms 83.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.54% over the past year.
The Earnings Per Share has been growing by 97.89% on average over the past years. This is a very strong growth
The Revenue has grown by 10.24% in the past year. This is quite good.
Measured over the past years, PGNY shows a very strong growth in Revenue. The Revenue has been growing by 59.52% on average per year.
EPS 1Y (TTM)11.54%
EPS 3Y97.89%
EPS 5YN/A
EPS Q2Q%-31.25%
Revenue 1Y (TTM)10.24%
Revenue growth 3Y46.69%
Revenue growth 5Y59.52%
Sales Q2Q%2.04%
3.2 Future
Based on estimates for the next years, PGNY will show a very strong growth in Earnings Per Share. The EPS will grow by 31.33% on average per year.
The Revenue is expected to grow by 8.60% on average over the next years. This is quite good.
EPS Next Y-9.78%
EPS Next 2Y-0.17%
EPS Next 3Y13.59%
EPS Next 5Y31.33%
Revenue Next Year4.76%
Revenue Next 2Y2.92%
Revenue Next 3Y5.71%
Revenue Next 5Y8.6%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 37.03, which means the current valuation is very expensive for PGNY.
The rest of the industry has a similar Price/Earnings ratio as PGNY.
When comparing the Price/Earnings ratio of PGNY to the average of the S&P500 Index (28.29), we can say PGNY is valued slightly more expensively.
PGNY is valuated quite expensively with a Price/Forward Earnings ratio of 34.76.
The rest of the industry has a similar Price/Forward Earnings ratio as PGNY.
PGNY's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.03 | ||
| Fwd PE | 34.76 |
4.2 Price Multiples
PGNY's Enterprise Value to EBITDA is on the same level as the industry average.
PGNY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PGNY is cheaper than 86.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.4 | ||
| EV/EBITDA | 20.57 |
4.3 Compensation for Growth
PGNY has a very decent profitability rating, which may justify a higher PE ratio.
PGNY's earnings are expected to grow with 13.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.17%
EPS Next 3Y13.59%
5. Dividend
5.1 Amount
No dividends for PGNY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROGYNY INC
NASDAQ:PGNY (1/21/2025, 8:20:21 PM)
After market: 21.5 +0.02 (+0.09%)21.48
+0.48 (+2.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.26%
Inst Owner Change-1.84%
Ins Owners6.57%
Ins Owner Change3.22%
Market Cap1.83B
Analysts76.25
Price Target19.23 (-10.47%)
Short Float %16.18%
Short Ratio6.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.36%
Min EPS beat(2)-19.12%
Max EPS beat(2)-1.61%
EPS beat(4)2
Avg EPS beat(4)6.11%
Min EPS beat(4)-19.12%
Max EPS beat(4)26.05%
EPS beat(8)6
Avg EPS beat(8)48.62%
EPS beat(12)10
Avg EPS beat(12)123.05%
EPS beat(16)13
Avg EPS beat(16)111.27%
Revenue beat(2)0
Avg Revenue beat(2)-3.87%
Min Revenue beat(2)-5.35%
Max Revenue beat(2)-2.39%
Revenue beat(4)0
Avg Revenue beat(4)-4.25%
Min Revenue beat(4)-5.82%
Max Revenue beat(4)-2.39%
Revenue beat(8)3
Avg Revenue beat(8)-1.11%
Revenue beat(12)5
Avg Revenue beat(12)-1.25%
Revenue beat(16)6
Avg Revenue beat(16)-1.42%
PT rev (1m)1.25%
PT rev (3m)-20.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-46.3%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.03 | ||
| Fwd PE | 34.76 | ||
| P/S | 1.61 | ||
| P/FCF | 11.4 | ||
| P/OCF | 11.11 | ||
| P/B | 4.21 | ||
| P/tB | 4.38 | ||
| EV/EBITDA | 20.57 |
EPS(TTM)0.58
EY2.7%
EPS(NY)0.62
Fwd EY2.88%
FCF(TTM)1.88
FCFY8.77%
OCF(TTM)1.93
OCFY9%
SpS13.37
BVpS5.11
TBVpS4.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 13.17% | ||
| ROCE | 14.5% | ||
| ROIC | 12.73% | ||
| ROICexc | 26.63% | ||
| ROICexgc | 28.94% | ||
| OM | 5.75% | ||
| PM (TTM) | 5.03% | ||
| GM | 21.68% | ||
| FCFM | 14.09% |
ROA(3y)10.72%
ROA(5y)8.95%
ROE(3y)15.14%
ROE(5y)13.15%
ROIC(3y)8.61%
ROIC(5y)7.94%
ROICexc(3y)19.38%
ROICexc(5y)20.33%
ROICexgc(3y)20.85%
ROICexgc(5y)26.41%
ROCE(3y)9.81%
ROCE(5y)9.05%
ROICexcg growth 3Y24.58%
ROICexcg growth 5YN/A
ROICexc growth 3Y31.27%
ROICexc growth 5YN/A
OM growth 3Y28.9%
OM growth 5YN/A
PM growth 3Y-24.95%
PM growth 5YN/A
GM growth 3Y2.58%
GM growth 5Y3.57%
F-Score7
Asset Turnover1.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 139.02% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 240.38% | ||
| Profit Quality | 280.06% | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z | 7.72 |
F-Score7
WACC9.25%
ROIC/WACC1.38
Cap/Depr(3y)175.37%
Cap/Depr(5y)143.9%
Cap/Sales(3y)0.39%
Cap/Sales(5y)0.55%
Profit Quality(3y)196.21%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.54%
EPS 3Y97.89%
EPS 5YN/A
EPS Q2Q%-31.25%
EPS Next Y-9.78%
EPS Next 2Y-0.17%
EPS Next 3Y13.59%
EPS Next 5Y31.33%
Revenue 1Y (TTM)10.24%
Revenue growth 3Y46.69%
Revenue growth 5Y59.52%
Sales Q2Q%2.04%
Revenue Next Year4.76%
Revenue Next 2Y2.92%
Revenue Next 3Y5.71%
Revenue Next 5Y8.6%
EBIT growth 1Y26.63%
EBIT growth 3Y89.07%
EBIT growth 5YN/A
EBIT Next Year128.6%
EBIT Next 3Y37.31%
EBIT Next 5Y26.82%
FCF growth 1Y363.59%
FCF growth 3Y73.98%
FCF growth 5Y155.82%
OCF growth 1Y336.49%
OCF growth 3Y73.42%
OCF growth 5Y142.1%